ACE-031 vs BPC-157
Emerging vs Extensively Studied
avoid Mechanism-based · 49% Both ACE-031 and BPC-157 have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision.
Molecular Data
ACE-031 BPC-157
Weight — 1,419.53 Da
Half-life 12-15 days <30 minutes
Chain — 15 amino acids
Type Soluble activin receptor type IIB-Fc fusion protein Pentadecapeptide
Key Benefits
ACE-031
01 Significant lean mass increases (up to 1.7% in 29 days) observed in Phase 1 trials
02 Simultaneous reduction in fat mass alongside muscle gains
03 Long half-life (12-15 days) allows infrequent dosing
04 Broad TGF-beta ligand neutralization for robust anti-catabolic effects
05 Dose-dependent increases in thigh muscle volume confirmed by MRI
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Dosing Protocols
ACE-031
0.5-3 mg/kg IV every 2 weeks (clinical research doses only) / Every 2 weeks
Phase 1 Research Protocol (Healthy Volunteers) 0.1-3 mg/kg Single IV dose
Phase 2 Research Protocol (DMD) 0.5-2.5 mg/kg Every 2 weeks
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Side Effects
ACE-031
Nosebleeds (epistaxis) - most frequently reported adverse event
Gum bleeding
Telangiectasia (dilated small blood vessels visible on skin)
Skin erythema (redness)
Minor injection site reactions
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Contraindications
NEVER approved for human use - clinical development discontinued
History of bleeding disorders or vascular malformations
Concurrent anticoagulant or antiplatelet therapy
Known hypersensitivity to Fc fusion proteins
Pregnancy or breastfeeding
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Research Evidence
ACE-031 BPC-157
Status Emerging Extensively Studied
References 4 studies 8 studies
Latest — July 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.